The binding of IGF-1 to the IGF-1 receptor on the CRC cells activates the mammalian target of the rapamycin (mTOR) pathway in the CRC cells, resulting in glucose uptake and lactate release. This evidence concerns the gene MTOR and colorectal carcinoma.